Imperial Immunologist Daniel Davis Advances NK Cell Research Through Bristol Myers Squibb Partnership

Daniel Davis, Head of Life Sciences at Imperial College London and MBE FMedSci, continues to push forward the understanding of immune system dynamics through his ongoing collaboration with Bristol Myers Squibb, building on his foundational discovery of the immunological synapse that has shaped cancer immunotherapy development for over two decades.

Speaking at WIRED Health, Davis detailed how his lab uses advanced microscopy to observe real-time immune cell behavior, particularly focusing on the molecular positioning that determines whether immune cells activate to kill cancer cells. The research centers on protein molecules positioned on immune cell surfaces that trigger immune responses — a mechanism Davis first characterized through his work on structured immune synapses for Natural Killer cells during his collaboration with Jack Strominger at Harvard University.

Current Research Pipeline

Davis's 2024 publications demonstrate the clinical trajectory of this foundational work. In August, his team published "Nanoscale re-structuring of the immune synapse with an engager enhances NK cell function" in Genes and Immunity, examining how molecular-level modifications can amplify NK cell cytotoxicity. The parallel study, "Prostaglandin E₂ impacts multiple stages of the natural killer cell antitumor immune response," published in the European Journal of Immunology, maps how inflammatory mediators interfere with NK cell activation pathways.

Both papers emerge from the ongoing Bristol Myers Squibb collaboration, reflecting the pharmaceutical industry's sustained investment in NK cell-based cancer therapeutics. The partnership leverages Davis's expertise in immune synapse architecture — the structured interface where immune cells make contact with target cells — to optimize therapeutic approaches that enhance natural killer cell function against malignancies.

Mechanistic Focus

The core insight driving this research stems from Davis's discovery that immune cell activation depends heavily on the precise spatial arrangement of signaling molecules. As he explained at WIRED Health, positioning molecules on immune cell surfaces determines whether cells receive the signals necessary to kill cancer cells. This spatial component represents a departure from earlier immunotherapy approaches that focused primarily on identifying target antigens without considering the geometric constraints of immune activation.

NK cells present particular advantages for therapeutic development because they operate independently of MHC class I presentation, allowing them to target cancer cells that have evolved mechanisms to evade T cell recognition. Davis's work on structured immune synapses provides the architectural framework for understanding how these cells can be enhanced to maintain cytotoxic function in the immunosuppressive tumor microenvironment.

Academic Impact and Recognition

The research program has generated substantial academic impact, with Davis authoring over 130 peer-reviewed papers that have accumulated more than 11,000 citations. Discover magazine recognized his work as one of the top 100 scientific breakthroughs, while his 2018 book "The Beautiful Cure: The Revolution in Immunology and What It Means for Your Health" earned recognition as Book of the Year from The Times, The Telegraph, and New Scientist.

This sustained output reflects the maturation of immune synapse research from basic discovery to therapeutic application — a progression I have observed repeatedly across biotechnology development cycles over the past three decades. The pattern typically involves a foundational discovery period, followed by mechanistic studies, then industrial partnerships that translate findings into clinical applications. Davis's trajectory exemplifies this evolution, moving from his initial Harvard work on NK cell architecture to current pharmaceutical collaborations targeting specific therapeutic modalities.

Technological Infrastructure

The microscopy capabilities that enable Davis's current research represent significant advances in real-time cellular imaging. The advanced microscopy systems his lab employs allow researchers to observe immune cell behavior with temporal and spatial resolution that was unavailable during earlier phases of immunotherapy development. This technological progression enables the detailed characterization of immune synapse dynamics that informs therapeutic design.

The integration of nanoscale imaging with functional assays provides the quantitative foundation for optimizing immune cell engagers — bispecific molecules designed to bring immune cells into productive contact with cancer cells. This approach moves beyond empirical screening toward rational design based on spatial and kinetic parameters of immune activation.

Industry Implications

The Bristol Myers Squibb collaboration positions this research within the broader pharmaceutical industry focus on next-generation immunotherapies. Following the clinical success of checkpoint inhibitors and CAR-T therapies, NK cell-based approaches represent an attempt to expand immunotherapy efficacy across patient populations and cancer types that remain resistant to current modalities.

The emphasis on immune synapse engineering addresses a fundamental limitation of existing immunotherapies: the inability to maintain immune cell function in hostile tumor environments. By optimizing the molecular architecture of immune activation, these approaches aim to sustain therapeutic activity even under conditions that typically suppress immune responses.

Looking forward, this research direction aligns with the industry trend toward combination therapies that address multiple mechanisms of immune evasion simultaneously. Davis's work on prostaglandin E₂ interference with NK cell function, for example, suggests potential combination strategies that could block immunosuppressive signals while enhancing immune cell activation through synapse optimization.

The convergence of advanced imaging, mechanistic understanding, and pharmaceutical partnership creates conditions for accelerated clinical translation — assuming the fundamental biology translates effectively from laboratory models to human therapeutic applications.